Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multip...

by Douglas L. Arnold, Shulian Shang, Qunming Dong, Matthias Meergans, Maria L. Naylor
Published 2018-08-01

Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.

by Steven M Rowe, Bo Liu, Aubrey Hill, Heather Hathorne, Morty Cohen, John R Beamer, Frank J Accurso, Qunming Dong, Claudia L Ordoñez, Anne J Stone, Eric R Olson, John P Clancy, VX06-770-101 Study Group
Published 2013-01-01